利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.021 秒)

    GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE FOR USE AS AN OSTEOTROPIC HORMONE
    13.
    发明公开
    GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE FOR USE AS AN OSTEOTROPIC HORMONE 有权
    葡萄糖依赖性，INSULINOTROPISCHES肽使用AS osteotropic激素

    公开(公告)号：EP1119625A1

    公开(公告)日：2001-08-01

    申请号：EP99950250.3

    申请日：1999-10-07

    申请人： Medical College Of Georgia Research Institute, Inc.

    发明人： ISALES, Carlos, M. ,  BOLLAG, Roni, J. ,  RASMUSSEN, Howard

    IPC分类号： C12N15/16 ,  C07K14/605 ,  C07K16/26 ,  A61K38/26 ,  A01K67/027

    CPC分类号： A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A61K38/00 ,  C07K14/605

    摘要： The examples demonstrate that GIP receptor mRNA and protein are present in normal bone and osteoblastic-like cell lines, and that high-affinity receptors for GIP can be demonstrated by 125 I GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated an increase in cellular cAMP content and in intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I mRNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblastic-like cells and that GIP modulates the function of these cells. GIP has anabolic actions on remodeling bone, increasing vertebral bone density in a rat model of osteoporosis. GIP at 10nM inhibits PTH-induced bone resorption in a fetal long bone assay and stimulates the synthesis of type 1 collagen mRNA. Transgenic mice overexpressing GIP have increased bone density compared to same age controls. GIP or analogs thereof can therefore be used as a therapeutic to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.

    Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
    19.
    发明公开
    Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance 审中-公开
    抗原呈递细胞群和他们的试剂进行放大或缩小免疫耐受的应用

    公开(公告)号：EP2177601A1

    公开(公告)日：2010-04-21

    申请号：EP09150154.4

    申请日：2002-04-12

    申请人： Medical College of Georgia Research Institute, Inc

    发明人： Mellor, Andrew ,  Munn, David

    IPC分类号： C12N5/00 ,  C12N5/02 ,  G01N33/53 ,  A61K45/00 ,  A61K47/00 ,  A01N63/00 ,  A01N65/00

    CPC分类号： C12N5/064 ,  A61K2035/122 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/70

    摘要： The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

    摘要翻译： 本发明是基于抗原 - 呈递细胞（APC）的发现可产生具有预定的胞内酶，吲哚胺2,3-双加氧酶（IDO）的表达水平。 因为高水平的IDO的表达与刺激T细胞应答的能力降低，并增强能力相关，以诱导免疫耐受，的APC具有高水平的IDO可用于增加公差在免疫系统中，如例如在移植疗法 或治疗自身免疫性疾病。 例如，具有高含量的IDO，并表达或装载有来自供体的组织的至少一种抗原的APC可用于增加接收者的耐受供体的组织。 可替代地，的APCs具有降低的IDO表达和表达的水平或装载有从癌症或感染性病原体的至少一种抗原可以用作疫苗促进T细胞应答和增加免疫力。